Breaking News

Amgen

April 11, 2007

Robert Bradway has been named executive vice president and chief financial officer, Amgen. He will be responsible for the company's finance, strategy and investor relations operations. Mr. Bradway replaces Richard Nanula, who is leaving the company to pursue other opportunities.

Mr. Bradway joined the company in 2006 as vice president, operations strategy. Prior to that, he spent 18 years at Morgan Stanley in New York and London, where he was a managing director in investment banking.

"Bob brings nearly 20 years of corporate finance experience to his new role and we are delighted to have him as part of our executive team," said Kevin Sharer, Amgen's chairman and chief executive officer. Mr. Nanula will remain at Amgen for the next 90 days to assist in the transition. "Richard has played an important role in Amgen's growth during the past six years, and I deeply appreciate his service to the company," said Mr. Sharer.

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks